3-(4-甲苯基)噻吩-2-羧酸 | 91368-47-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 噻吩类
• 中文名称: 3-(4-甲苯基)噻吩-2-羧酸
• 英文名称: 3-p-tolyl-thiophene-2-carboxylic acid
• 英文别名: 3-(4-methylphenyl)thiophene-2-carboxylic Acid
• CAS: 91368-47-7
• 化学式: C₁₂H₁₀O₂S
• mdl: MFCD07323336
• 分子量: 218.276
• InChiKey: GCEHBBDKPSCJCF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.083
• 拓扑面积：
  65.5
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  3-(4-甲苯基)噻吩-2-羧酸 在 lithium perchlorate 作用下， 以 乙腈 为溶剂， 反应 5.0h， 以70%的产率得到7-methyl-4H-thieno[2,3-c]chromen-4-one
  参考文献：
  名称：

  电化学C-O键形成：容易获得芳香内酯

  摘要：

  描述了一种基于电化学技术的有效且稳健的方法，用于通过脱氢C-O环化反应直接合成芳族内酯。这种新的有用的电化学反应可以耐受各种官能团，在温和条件下可扩展至100 g。值得注意的是，可以使用含杂环的底物，从而扩大了自由基C-O环化反应的范围。

  DOI：

  10.1002/chem.201801108
• 作为产物：
  描述：

  3-溴噻吩-2-甲酸 、 4-甲苯硼酸 生成 3-(4-甲苯基)噻吩-2-羧酸
  参考文献：
  名称：

  Trans-3-aza-bicyclo[3.1.0]hexane derivatives

  摘要：

  本发明涉及一种新的式子(I)的trans-3-aza-bicyclo[3.1.0]hexane衍生物，其中A、B、n和R1如描述中所述，以及使用这种化合物或这种化合物的药学上可接受的盐作为药物，特别是作为促进睡眠的药物。

  公开号：

  US08063099B2

文献信息

• Rhodium‐Catalyzed <i>ortho</i> ‐Arylation of (Hetero)aromatic Acids
  作者：Philip Weber、Christian K. Rank、Enis Yalcinkaya、Marco Dyga、Tim van Lingen、Rochus Schmid、Frederic W. Patureau、Lukas J. Gooßen

  DOI：10.1002/adsc.201900596

  日期：2019.9.3

  Rhodium acetate effectively promotes the carboxylate‐directed ortho‐arylation of (hetero)aromatic carboxylates with aryl bromides. The main advantage of this phosphine‐free, redox‐neutral method arises from its efficiency in assembling biologically meaningful electron‐rich arylpyridines, which are problematic substrates in known C−H arylations using Pd, Ru, and Ir catalysts.

  乙酸铑有效地促进了（杂）芳族羧酸盐与芳基溴化物的羧酸盐定向邻位芳基化。这种无膦，氧化还原中性方法的主要优点来自于它在组装具有生物学意义的富电子芳基吡啶方面的效率，这些芳基吡啶是已知的使用Pd，Ru和Ir催化剂在CH芳基化中存在问题的底物。
• TRANS-3-AZA-BICYCLO[3.1.0]HEXANE DERIVATIVES
  申请人：Aissaoui Hamed

  公开号：US20100204285A1

  公开（公告）日：2010-08-12

  The invention relates to novel trans-3-aza-bicyclo[3.1.0]hexane derivatives of formula (I), wherein A, B, n and R 1 are as described in the description, and to the use of such compounds, or of pharmaceutically acceptable salts of such compounds, as medicaments, especially as orexin receptor antagonists.

  该发明涉及新的式子（I）中的trans-3-aza-bicyclo[3.1.0]hexane衍生物，其中A、B、n和R1如说明书所述，并且涉及使用这样的化合物或这样的化合物的药学上可接受的盐作为药物，特别是作为促进睡眠的药物。
• In Silico-Aided Design of a Glycan Ligand of Sialoadhesin for in Vivo Targeting of Macrophages
  作者：Corwin M. Nycholat、Christoph Rademacher、Norihito Kawasaki、James C. Paulson

  DOI：10.1021/ja307501e

  日期：2012.9.26

  Cell-specific delivery of therapeutic agents using ligand targeting is gaining interest because of its potential for increased efficacy and reduced side effects. The challenge is to develop a suitable ligand for a cell-surface receptor that is selectively expressed on the desired cell. Sialoadhesin (Sn, Siglec-1, CD169), a sialic acid-binding immunoglobulin-like lectin (Siglec) expressed on subsets of resident and inflammatory macrophages, is an attractive target for the development of a ligand-targeted delivery system. Here we report the development of a high-affinity and selective ligancl for Sn that is an analogue of the natural ligand and is capable of targeting liposomal nanoparticles to Sn-expressing cells in vivo. An efficient in silico screen of a library of similar to 8400 carboxylic acids was the key to identifying novel 9-N-acyl-substituted N-acetylneuramic acid (Neu5Ac) substituents as potential lead compounds. A small panel of targets were selected from the screen and synthesized to evaluate their affinities and selectivities. The most potent of these Sn ligands, (4H-thieno[3,2-c]chromene-2-carbamoyl)-Neu5Ac alpha 2-3Gal beta 1-4GlcNAc ((TCC)Neu5Ac), was conjugated to lipids for display on a liposomal nanoparticle for evaluation of targeted delivery to cells. The (TCC)Neu5Ac liposomes were found to target liposomes selectively to cells expressing either murine or human Sn in vitro, and when administered to mice, they exhibited in vivo targeting to Sn-positive macrophages.
• US5358950A
  申请人：——

  公开号：US5358950A

  公开（公告）日：1994-10-25
• US8063099B2
  申请人：——

  公开号：US8063099B2

  公开（公告）日：2011-11-22